If national competent authorities, the Agency or the Commission have concerns about the safety of a medicinal product, they may oblige a marketing authorisation holder to initiate, manage and finance non-interventional post-authorisation safety studies. In order for them to be transparent, the marketing authorisation holder should put such studies in the electronic post-authorisation study register maintained by the Agency.
Recital 10, Regulation (EU) 2025/1466
In forcesince 22 Jul 2025